<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39389076</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(24)00423-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(24)00423-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia virus Ankara (MVA). In this study, the safety, immunogenicity, and optimal dose schedule of MVA-MERS-S was assessed in individuals with previous exposure to SARS-CoV-2 infections and vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a multicentre, double-blind, randomised controlled phase 1b clinical trial at two university medical centres in Germany and the Netherlands. Healthy volunteers aged 18-55 years were assigned by computer randomisation to receive three intramuscular injections of 10<sup>7</sup> or 10<sup>8</sup> plaque-forming units (PFU) of MVA-MERS-S, with two treatment groups each of either 28-day or 56-day intervals between the initial two doses, and one control arm that received only placebo, at a ratio of 2:2:2:2:1. The third dose was given after 224 days. The sponsor, clinical and laboratory staff, and participants were masked to both vaccine dose and dosing interval. The primary outcome was safety, assessed in the all participants who had received at least one injection; daily solicited vaccine reactions were recorded after each dose for 7 days, unsolicited adverse events for 28 days, and serious adverse events throughout the study. The secondary outcome was humoral immunogenicity, measured with vaccine-induced geometric mean antibody concentrations and seroconversion rates, analysed in all participants who received at least three allocated treatments. This study is registered at ClinicalTrials.gov (NCT04119440) and is completed.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between 26 July, 2021, and 3 March, 2022, 244 volunteers were screened, 177 of whom were eligible and 140 were randomly assigned either to the 28-day 10<sup>7</sup> PFU group (n=32), 56-day 10<sup>7</sup> PFU group (n=31), 28-day 10<sup>8</sup> PFU group (n=31), 56-day 10<sup>8</sup> PFU group (n=30), or placebo group (n=16). In total, 178 doses were administered of 10<sup>7</sup> PFU of MVA-MERS-S, 174 of 10<sup>8</sup> PFU, and 164 doses of placebo, and 139 participants received at least one injection. 73 (53%) were female and 66 (48%) were male. No serious vaccine-related adverse events occurred. Solicited local reactions were mild in 288 (93%, 95% CI 90-96) of 309 reports and consisted primarily of pain or tenderness. Pain or tenderness (of any severity) occurred after 69 (39%, 32-46) of 178 10<sup>7</sup> PFU injections, 138 (79%; 73-85) of 174 10<sup>8</sup> PFU injections, and 18 (11%; 7-11) of 164 placebo injections. Of 595 reported solicited systemic reactions, 479 (81%, 77-83) were graded as mild. Systemic reactions of any grade occurred after 77 (43%; 36-51) 10<sup>7</sup> PFU injections, 102 (59%; 51-66) 10<sup>8</sup> PFU injections, and 67 (41%; 34-49) of 164 placebo injections. At 28 days after the second dose, MERS-CoV neutralising antibodies were highest for participants assigned to 56-day 10<sup>8</sup> PFU, with geometric mean ratios of 7·2 (95% CI 3·9-13·3) for the 56-day 10<sup>8</sup> PFU group versus the 28-day 10<sup>8</sup> PFU group (p&lt;0·0001), 3·9 (2·1-7·2) for the 56-day 10<sup>8</sup> PFU group versus the 56-day 10<sup>7</sup> PFU group (p=0·0031), and 5·4 (2·9-10·0) for the 56-day 10<sup>8</sup> PFU group versus the 28-day 10<sup>7</sup> PFU group (p=0·0003).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">MVA-MERS-S was safe and immunogenic in individuals with previous and concurrent SARS-CoV-2 exposure. The second vaccination with the 10<sup>8</sup> PFU dose of MVA-MERS-S elicited a stronger humoral immune response when administered 56 days after the first dose than a 28-day interval. Further studies are needed to verify these findings in groups at risk for MERS-CoV exposure, and at risk of severe disease, including older individuals and those with relevant comorbidities.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Coalition for Epidemic Preparedness Innovations, the German Centre for Infection Research, and the German Research Foundation.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raadsen</LastName><ForeName>Matthijs P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahlke</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Hamburg-Lübeck-Borstel-Riems partner site, German Centre for Infection Research, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fathi</LastName><ForeName>Anahita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Hamburg-Lübeck-Borstel-Riems partner site, German Centre for Infection Research, Hamburg, Germany; First Department of Medicine, Division of Infectious Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardtke</LastName><ForeName>Svenja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Hamburg-Lübeck-Borstel-Riems partner site, German Centre for Infection Research, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klüver</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; Gießen-Marburg-Langen partner site, German Center for Infection Research, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krähling</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; Gießen-Marburg-Langen partner site, German Center for Infection Research, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerresheim</LastName><ForeName>Gesche K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; Gießen-Marburg-Langen partner site, German Center for Infection Research, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Leonie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Hamburg-Lübeck-Borstel-Riems partner site, German Centre for Infection Research, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mykytyn</LastName><ForeName>Anna Z</ForeName><Initials>AZ</Initials><AffiliationInfo><Affiliation>Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weskamm</LastName><ForeName>Leonie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Hamburg-Lübeck-Borstel-Riems partner site, German Centre for Infection Research, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoran</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Hamburg-Lübeck-Borstel-Riems partner site, German Centre for Infection Research, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Gorp</LastName><ForeName>Eric C M</ForeName><Initials>ECM</Initials><AffiliationInfo><Affiliation>Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany; German Centre for Infection Research, Munich partner site, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology, Philipps University of Marburg, Marburg, Germany; Gießen-Marburg-Langen partner site, German Center for Infection Research, Marburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haagmans</LastName><ForeName>Bart L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Viroscience, Erasmus Medical Centre, Rotterdam, Netherlands. Electronic address: b.haagmans@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addo</LastName><ForeName>Marylyn M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute for Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; Hamburg-Lübeck-Borstel-Riems partner site, German Centre for Infection Research, Hamburg, Germany; First Department of Medicine, Division of Infectious Diseases, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. Electronic address: m.addo@uke.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>MVA-MERS-S_DF-1 Study group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04119440</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of interests AF became a full-time employee of BioNTech in January, 2024, after completion of this study. CD has been the translational immunology lead at the Coalition for Epidemic Preparedness Innovations (CEPI) since November, 2022, with responsibilities separate from her role in the present study. BLH is named as an inventor on a patent related to MERS-CoV. SB and GS are named as inventors on a patent for a novel MERS-CoV vaccine. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Borregaard</LastName><ForeName>Saskia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaltenberg</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelidou</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hesterkamp</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwamborn</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schröder</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dieck</LastName><ForeName>Marie-Louise</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedrich</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grüttner</LastName><ForeName>Cordula</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ly</LastName><ForeName>My Linh</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mellinghoff</LastName><ForeName>Sybille</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renevier</LastName><ForeName>Niclas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rottstegge</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandkuhl</LastName><ForeName>Maren</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlesner</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volz</LastName><ForeName>Asisa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Funk</LastName><ForeName>Jana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kardinahl</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neubert</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalomidou</LastName><ForeName>Georgia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tscherne</LastName><ForeName>Alina</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kupke</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39389076</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(24)00423-7</ArticleId><ArticleId IdType="pii">S1473-3099(24)00423-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle>